I
Imexpharm Corp
VN:IMP
Imexpharm Corp
VN:IMP
Price:
48 050
VND
-0.93%
Market Closed
Market Cap:
7.4T
VND
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
IMP Alert
Imexpharm Corp
48050
-450 (-0.93%)
| 52 Week Range |
25 066.1469
97 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches VND.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Imexpharm Corp
Balance Sheet
Balance Sheet Decomposition
Imexpharm Corp
Imexpharm Corp
| Current Assets | 1.5T |
| Cash & Short-Term Investments | 270.4B |
| Receivables | 371.5B |
| Other Current Assets | 824.9B |
| Non-Current Assets | 1.1T |
| Long-Term Investments | 71.3B |
| PP&E | 862.1B |
| Intangibles | 74.8B |
| Other Non-Current Assets | 106.8B |
| Current Liabilities | 431.6B |
| Accounts Payable | 111B |
| Accrued Liabilities | 106.9B |
| Short-Term Debt | 104.2B |
| Other Current Liabilities | 109.5B |
Balance Sheet
Imexpharm Corp
Imexpharm Corp
Currency: VND
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
50 050
|
87 842
|
100 127
|
106 457
|
190 437
|
75 036
|
85 269
|
271 273
|
178 845
|
106 201
|
|
| Cash |
50 050
|
42 842
|
100 127
|
86 457
|
60 437
|
75 036
|
84 093
|
46 273
|
88 845
|
106 201
|
|
| Cash Equivalents |
0
|
45 000
|
0
|
20 000
|
130 000
|
0
|
1 176
|
225 000
|
90 000
|
0
|
|
| Short-Term Investments |
3 283
|
103 568
|
15 393
|
183 046
|
4 281
|
5 188
|
63 608
|
112 453
|
211 300
|
93 000
|
|
| Total Receivables |
220 568
|
252 323
|
249 490
|
263 217
|
235 545
|
292 348
|
365 237
|
279 597
|
248 970
|
267 128
|
|
| Accounts Receivables |
199 132
|
214 185
|
211 038
|
218 062
|
172 994
|
239 811
|
317 988
|
234 564
|
217 383
|
254 058
|
|
| Other Receivables |
21 436
|
38 139
|
38 451
|
45 155
|
62 551
|
52 536
|
47 249
|
45 033
|
31 586
|
13 070
|
|
| Inventory |
294 567
|
245 719
|
234 563
|
282 179
|
323 809
|
350 457
|
424 237
|
492 075
|
435 841
|
699 446
|
|
| Other Current Assets |
22 314
|
55 249
|
121 506
|
142 644
|
80 671
|
56 727
|
43 625
|
20 942
|
28 597
|
41 361
|
|
| Total Current Assets |
719 282
|
744 701
|
721 079
|
977 543
|
834 742
|
779 755
|
981 975
|
1 176 340
|
1 103 553
|
1 207 135
|
|
| PP&E Net |
177 044
|
207 271
|
275 303
|
619 039
|
790 282
|
896 180
|
949 147
|
955 680
|
996 450
|
908 754
|
|
| PP&E Gross |
177 044
|
207 271
|
275 303
|
619 039
|
790 282
|
896 180
|
949 147
|
955 680
|
996 450
|
908 754
|
|
| Accumulated Depreciation |
214 399
|
251 087
|
285 235
|
310 845
|
332 536
|
367 020
|
414 061
|
464 356
|
521 395
|
589 503
|
|
| Intangible Assets |
1 813
|
71 340
|
70 754
|
72 353
|
72 728
|
71 082
|
76 563
|
73 581
|
72 978
|
74 150
|
|
| Note Receivable |
220
|
76
|
80
|
50
|
3 550
|
2 420
|
50
|
50
|
50
|
2 257
|
|
| Long-Term Investments |
46 228
|
48 602
|
60 917
|
65 797
|
41 094
|
51 678
|
51 669
|
50 962
|
71 290
|
71 284
|
|
| Other Long-Term Assets |
84 950
|
20 725
|
27 712
|
38 848
|
31 851
|
46 060
|
37 051
|
38 086
|
32 622
|
129 035
|
|
| Total Assets |
1 029 539
N/A
|
1 092 715
+6%
|
1 155 845
+6%
|
1 773 631
+53%
|
1 774 247
+0%
|
1 847 174
+4%
|
2 096 455
+13%
|
2 294 700
+9%
|
2 276 944
-1%
|
2 392 615
+5%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
112 795
|
56 006
|
88 703
|
224 903
|
109 020
|
90 859
|
59 704
|
92 713
|
85 923
|
70 505
|
|
| Accrued Liabilities |
77 026
|
71 647
|
91 827
|
105 739
|
103 649
|
100 102
|
106 282
|
93 997
|
135 102
|
139 452
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
37 579
|
130 928
|
172 143
|
94 980
|
49 422
|
|
| Other Current Liabilities |
10 507
|
28 786
|
17 601
|
13 214
|
23 809
|
33 914
|
50 019
|
49 786
|
66 492
|
48 658
|
|
| Total Current Liabilities |
200 327
|
156 439
|
198 131
|
343 855
|
236 478
|
262 454
|
346 932
|
408 638
|
382 497
|
308 036
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
91 652
|
0
|
0
|
|
| Other Liabilities |
32 575
|
29 445
|
21 798
|
34 461
|
33 156
|
25 831
|
19 037
|
0
|
0
|
0
|
|
| Total Liabilities |
232 902
N/A
|
185 884
-20%
|
219 929
+18%
|
378 317
+72%
|
269 634
-29%
|
288 285
+7%
|
365 969
+27%
|
500 290
+37%
|
382 497
-24%
|
308 036
-19%
|
|
| Equity | |||||||||||
| Common Stock |
263 115
|
289 426
|
289 426
|
429 782
|
494 212
|
494 212
|
667 054
|
667 054
|
667 054
|
700 384
|
|
| Retained Earnings |
80 229
|
85 050
|
91 555
|
96 281
|
125 091
|
157 795
|
205 237
|
197 424
|
264 645
|
440 095
|
|
| Additional Paid In Capital |
238 958
|
297 734
|
297 714
|
601 241
|
601 241
|
601 241
|
507 368
|
507 368
|
507 368
|
507 368
|
|
| Treasury Stock |
0
|
0
|
124
|
219
|
219
|
359
|
359
|
359
|
359
|
359
|
|
| Other Equity |
214 335
|
234 621
|
257 345
|
268 229
|
284 288
|
306 001
|
351 186
|
422 922
|
455 738
|
437 089
|
|
| Total Equity |
796 636
N/A
|
906 831
+14%
|
935 916
+3%
|
1 395 314
+49%
|
1 504 613
+8%
|
1 558 889
+4%
|
1 730 486
+11%
|
1 794 410
+4%
|
1 894 447
+6%
|
2 084 579
+10%
|
|
| Total Liabilities & Equity |
1 029 539
N/A
|
1 092 715
+6%
|
1 155 845
+6%
|
1 773 631
+53%
|
1 774 247
+0%
|
1 847 174
+4%
|
2 096 455
+13%
|
2 294 700
+9%
|
2 276 944
-1%
|
2 392 615
+5%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
35
|
50
|
48
|
64
|
64
|
64
|
70
|
77
|
77
|
77
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
